Molly Billstein Leber, PharmD, BCPS, FASHP

Molly Billstein Leber, PharmD, BCPS, FASHP, is manager, Medication Policy and Formulary Management, Yale New Haven System in New Haven, Connecticut. She received her PharmD degree from the University of Montana and completed a PGY1 Residency at Yale New Haven Hospital. Leber’s career focuses on formulary standardization, drug use policy, pharmacy informatics, and promoting safe and efficient use of medications.

ODAC Rule on Anticancer Biosimilars Invigorates Discussion on Extrapolation

Jul 18, 2017 @06:30 PM

SCOTUS Ruling on 6-Month Notice Period for Biosimilars: Formulary and Cost Impact

Jun 24, 2017 @01:49 PM

Formulary Management an Important Consideration for Biosimilar Stakeholders

Jun 1, 2017 @01:17 PM

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512

P: 609-716-7777
F: 609-716-4747